Names and pronunciation
(per-am′i-vir) Rapivab
PDF page 1041
Loading InternPractice…
Drug reference
(per-am′i-vir) Rapivab
PDF page 1041
Func. class.: Antiviral
PDF page 1041
ACTION: Competitively binds to the active site of the influenza virus, inhibits the activity of strains of influenza A and B viruses
PDF page 1041
USES: Treatment of uncomplicated acute influenza (seasonal influenza A virus infection or seasonal influenza B virus infection)
PDF page 1041
Unlabeled uses: Treatment of H1N1 influenza A virus (swine influenza) infection
PDF page 1041
CONTRAINDICATIONS: Serious hypersensitivity Precautions: Breastfeeding, children, dialysis, infants, infection, pregnancy, psychosis, renal impairment
PDF page 1042
SIDE EFFECTS CNS: Delirium, psychosis, hallucina- tions, insomnia GI: Constipation, diarrhea, vomiting MISC: Rash, Stevens-Johnson syndrome, anaphylaxis
PDF page 1042
INTERACTIONS Avoid use with intranasal influenza vac- cines, H1N1 vaccines
PDF page 1042
DOSAGE AND ROUTES Influenza • Adult: IV 600 mg as a single dose in- fused over 15-30 min, give within 48 hr of onset of influenza symptoms Renal Dose Adult/adolescent: CCr ≥50 mL/min, no change; CCr 30-40 mL/min, 200 mg as a single dose; CCr 10-29 mL/min, 100 mg as a single dose
PDF page 1042
Available forms: Solution for injection 200 mg/20 mL
PDF page 1042
Administer: • For IV use only, do not give IM, visually inspect parenteral products for particu- late matter and discoloration • Dilute the 10 mg/mL to a max volume of 100 mL, use only 0.9% or 0.45% NaCl, 5% dextrose, or LR • Storage of diluted solution: Use immedi- ately or refrigerate up to 24 hr. Refrigerated solution should be allowed to reach room temperature before administration. Discard any unused diluted solution after 24 hr • Give over 15-30 min, do not mix or coadminister with other IV products
PDF page 1042
Assess: • Hypersensitivity reactions/Stevens- Johnson syndrome • Neuropsychiatric reactions: delirium, psychosis, hallucinations
PDF page 1042
Evaluate: • Therapeutic response: absence of de- veloping influenza A or B
PDF page 1042
CLINICAL CONSIDERATIONS
PDF page 1042
Patient and caregiver information: • That product is for use only within 48 hr of symptoms
PDF page 1042
PHARMACOKINETICS Protein binding <30%
PDF page 1042
• Adult: IV 600 mg as a single dose in- fused over 15-30 min, give within 48 hr of onset of influenza symptoms Renal Dose Adult/adolescent: CCr ≥50 mL/min, no change; CCr 30-40 mL/min, 200 mg as a single dose; CCr 10-29 mL/min, 100 mg as a single dose
PDF page 1042